Patents Issued in December 26, 2017
  • Patent number: 9849095
    Abstract: Provided is an adhesive patch containing ropinirole serving as a therapeutic drug for Parkinson's disease, with the ropinirole used being free ropinirole (ropinirole in free form) added to an adhesive base, wherein the patch exhibits favorable drug permeability and excellent drug stability. Also provided is a transdermal absorption patch using, as an adhesive base, an acrylic-based adhesive having no specific carboxyl group and having a hydroxyl group or a pyrrolidone group, with the patch including free ropinirole added to the adhesive base. Further provided is a ropinirole-containing transdermal absorption patch including a transdermal absorption promoting agent.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: December 26, 2017
    Assignee: Teikoku Seiyaku Co., Ltd.
    Inventors: Katsuyuki Inoo, Akiko Katayama, Daiki Takano
  • Patent number: 9849096
    Abstract: The present invention provides use of composition containing molecular dispersions of carotenoids for the prevention of neurodegenerative disorders which are safe for human consumption and are particularly useful as dietary supplements for nutrition and health promoting benefits. The present invention particularly relates to the use of highly water soluble composition with enhanced bioavailability containing at least 80% by weight of total xanthophylls, out of which the trans-lutein content is 80-95% w/w; (R,R)-zeaxanthin is 14-20% w/w; (R,S)-zeaxanthin is 0.01-1% w/w and traces of other carotenoids derived from the plant extracts/oleoresin containing xanthophylls/xanthophylls esters. The present invention also provides use of the said composition in treatment of neurodegenerative disorders when co-administered along with reduced dose of Levodopa and Carbidopa.
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: December 26, 2017
    Assignee: OmniActive Health Technologies Limited
    Inventors: Jayant Deshpande, J. Shankaranarayanan
  • Patent number: 9849097
    Abstract: A modified release oral dosage form comprising an internal phase containing terbutaline sulphate and a pharmaceutically acceptable excipient, dispersed in an external phase comprising pharmaceutically acceptable excipients.
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: December 26, 2017
    Assignee: Jagotec AG
    Inventors: Alain Nhamias, Nasser Beniou
  • Patent number: 9849098
    Abstract: A method for treating a respiratory injury or disease comprising: administering to a patient in need of treatment a pharmaceutical composition comprising a compound of general Formula I: or salt, ester, solvate, hydrate, or prodrug thereof; wherein: x is an integer from 1 to 10; A and B are each, independently, C3-7 cycloalkyl, C3-7 cycloalkyl-C1-6alkyl, C3-7 heterocycloalkyl, C3-7 heterocycloalkyl-C1-6 alkyl, C6-10aryl, C6-10aryl-C1-6alkyl, C3-9 heteroaryl, or C3-9heteroaryl-C1-6alkyl; and n and p are each, independently, integers from 1 to 10; and a pharmaceutically acceptable carrier, excipient, or diluent.
    Type: Grant
    Filed: December 9, 2014
    Date of Patent: December 26, 2017
    Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education, The United States of America as represented by the Department of Veterans Affairs
    Inventors: Beibei Chen, Rama Mallampalli
  • Patent number: 9849099
    Abstract: Described herein are antimicrobial compounds identified via a high-throughput screen to identify compounds that produce anucleate cells in E. coli after cell division occurs. Compound 1 (5-nonyloxytryptamine) and its analogs are small molecule inhibitors of the nucleoid occlusion system and/or proteins that are responsible for maintaining the structure of the chromosome. The antimicrobial compounds are useful to treat bacterial infections as well as to inhibit bacterial growth.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: December 26, 2017
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Douglas Benjamin Weibel, Katherine Ann Hurley, Katherine Cassidy Faulkner
  • Patent number: 9849100
    Abstract: The invention relates to aqueous suspension pharmaceutical compositions of poorly water soluble drugs, wherein said drugs are selected from compounds of formula (I) (Formula (I)), wherein R1-R9 are defined herein; processes for preparing these compositions and their use in medicine, especially their use in the treatment of ocular diseases.
    Type: Grant
    Filed: January 9, 2014
    Date of Patent: December 26, 2017
    Assignee: Kalvista Pharmaceuticals Limited
    Inventors: Gary Paul Cook, Garry Thomas Gwozdz, Theodore Patrick Laslo
  • Patent number: 9849101
    Abstract: A method for enhancing amidohydrolase activity of Fatty Acid Amide Hydrolase (FAAH) is disclosed. The method comprising administering a phenoxyacyl-ethanolamide that causes the enhanced activity. The enhanced activity can have numerous effects on biological organisms including, for example, enhancing the growth of certain seedlings.
    Type: Grant
    Filed: September 15, 2016
    Date of Patent: December 26, 2017
    Assignees: Research Foundation of the City University of New York, The Curators of the University of Missouri, University of North Texas
    Inventors: George John, Subbiah Nagarajan, Kent Chapman, Lionel Faure, Peter Koulen
  • Patent number: 9849102
    Abstract: A method of treating endometriosis in a person by reducing a cytokine MCP-1 related activity level of an endometriosis implant in said person by 50% or more while not affecting a corresponding TNF-? related activity level by more than 30% comprises providing a pharmaceutical composition comprising a local anaesthetic, in particular lidocaine hydrochloride, and a pharmaceutically acceptable carrier, administering the composition intraperitoneally to said person, thereby substantially reducing the recruitment of macrophages by MCP-1 released from the endometriosis implant. Also disclosed is a corresponding pharmaceutical composition.
    Type: Grant
    Filed: May 13, 2011
    Date of Patent: December 26, 2017
    Assignee: ISIFER AB
    Inventor: Greta Edelstam
  • Patent number: 9849103
    Abstract: The present invention discloses anti-cancer compositions, and associated methods, including an anti-cancer composition comprising: a cellular energy inhibitor having the structure according to formula I wherein X is selected from the group consisting of: a nitro, an imidazole, a halide, sulfonate, a carboxylate, an alkoxide, and amine oxide; and R is selected from the group consisting of: OR?, N(R?)2, C(O)R??, C1-C6 alkyl, C6-C12 aryl, C1-C6 heteroalkyl, a C6-C12 heteroaryl, H, and an alkali metal; where R? represents H, alkali metal, C1-C6 alkyl, C6-C12 aryl or C(O)R??, R? represents H, C1-C6 alkyl, or C6-C12 aryl, and R?? represents H, C1-C20 alkyl or C6-C12 aryl. The anti-cancer composition can additionally comprise at least one sugar, which stabilizes the cellular energy inhibitor by substantially preventing the inhibitor from hydrolyzing. Also, the anti-cancer composition can comprise a hexokinase inhibitor.
    Type: Grant
    Filed: October 6, 2015
    Date of Patent: December 26, 2017
    Inventor: Young Hee Ko
  • Patent number: 9849104
    Abstract: Methods and formulations to reduce elevated levels of lipids and apolipoprotein B in subjects having type IIb hyperlipidemia. Methods for preventing, delaying or regressing complications of lipid disorders, including; type IIb hyperlipidemia, NAFLD, and NASH. Methods for preventing or delaying primary and secondary cardiovascular events. Kits useful for such methods. Methods for reducing hepatic fibrosis. Methods for reducing plasma fibrinogen levels.
    Type: Grant
    Filed: January 26, 2017
    Date of Patent: December 26, 2017
    Assignee: Gemphire Therapeutics Inc.
    Inventors: Charles L. Bisgaier, Daniela Carmen Oniciu
  • Patent number: 9849105
    Abstract: Invention pertains to a free-flowing particulate powder including 2-90 wt. % of an active compound on a carrier, wherein the carrier has a D(v,0.1) of at least 100 microns, with the active compound being selected from lactylate in accordance with formula (1), Formula (1): R2-COO—[—CH(CH3)-COO]n-R1 or a Na, K, Ca, Mg, Fe(II), Zn, NH4, or Cu(II) salt thereof, a glycolylate of formula (2), Formula (2): R2-COO—[—CH2-COO]n-R1 or a Na, K, Ca, Mg, Fe(II), Zn, NH4, or Cu(II) salt thereof a lactate ester of formula (3), Formula (3): HO—CH(CH3)-COO—R2 and/or a glycolic acid ester of formula (4), Formula (4): HO—CH2-COO—R2 wherein in the above formulae R1 is selected from H, n stands for an integer with a value of 1-10, and R2 stands for a C1-C35 alkyl or alkenyl chain which may be branched or unbranched. The powder allows easy provision of the active compound to feed compositions.
    Type: Grant
    Filed: July 3, 2012
    Date of Patent: December 26, 2017
    Assignee: PURAC BIOCHEM BV
    Inventors: Symone Kok, Nikolaos Vogiatzis
  • Patent number: 9849106
    Abstract: The invention generally relates to methods of treating a patient suffering from renal disorders or other disorders related to low levels of sRAGE, and/or low levels of adiponectin (e.g., high molecular weight adiponectin) and/or high levels of thrombomodulin, using effective of amounts of a MetAP-2 inhibitor.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: December 26, 2017
    Assignee: Zafgen, Inc.
    Inventors: Thomas E. Hughes, James E. Vath
  • Patent number: 9849107
    Abstract: Methods of inhibiting cytochrome P450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome P450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome P450 enzymes.
    Type: Grant
    Filed: January 11, 2016
    Date of Patent: December 26, 2017
    Assignee: SEQUOIA PHARMACEUTICALS, INC.
    Inventors: Michael Eissenstat, Dehui Duan
  • Patent number: 9849108
    Abstract: A composition is provided that includes a cannabinoid capable of inducing a pharmacological effect, an ester, a condensation aerosol, and a carrier liquid solution of food grade materials. The cannabinoid may include a bio-active ingredient receivable by a cannabinoid receptor and/or an acetylcholine receptor. The pharmacological effect may be produced by reception of tetrahydrocannabinol, cannabidiol, or mixtures thereof. The composition may also include ethanol, flavoring agents, and aromatherapy agents. The composition is deliverable to a user via vaporization. A method is provided for creating a pharmacological effect using the composition.
    Type: Grant
    Filed: May 2, 2016
    Date of Patent: December 26, 2017
    Inventor: Stephen C. Perry
  • Patent number: 9849109
    Abstract: Described herein are compounds that are inhibitors of autotaxin. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such inhibitors, alone and in combination with other compounds, for treating autotaxin-dependent or autotaxin-mediated conditions or diseases.
    Type: Grant
    Filed: February 23, 2015
    Date of Patent: December 26, 2017
    Assignee: AMIRA PHARMACEUTICALS, INC.
    Inventors: Jeffrey Roger Roppe, Timothy Andrew Parr, Nicholas Simon Stock, Deborah Volkots, John Howard Hutchinson
  • Patent number: 9849110
    Abstract: The present specification discloses compositions comprising a pharmaceutical composition to reduce or maintain LDL and/or cholesterol levels in an individual and a plurality of therapeutic compounds to increase or maintain HDL levels in an individual. The present specification also discloses a treatment protocol wherein a pharmaceutical composition is administered to an individual on a schedule wherein the pharmaceutical composition is provided for a period of time and then not provided to the individual and this treatment protocol is repeated for the term of the individual's treatment.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: December 26, 2017
    Assignee: Biocopea Limited
    Inventors: John Brew, Robin Mark Bannister
  • Patent number: 9849111
    Abstract: The present invention relates to methods for producing particles of indomethacin using dry milling processes as well as compositions comprising indomethacin, medicaments produced using indomethacin in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of indomethacin administered by way of said medicaments.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: December 26, 2017
    Assignee: iCeutica Pty Ltd.
    Inventors: Aaron Dodd, Felix Meiser, Marck Norret, Adrian Russell, H. William Bosch
  • Patent number: 9849112
    Abstract: Pyrrole compounds as Granzyme B inhibitors, compositions that include the compounds, and methods for using the compounds. Method for treating cutaneous scleroderma, epidermolysis bullosa, radiation dermatitis, alopecia areata, and discoid lupus erythematosus are provided.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: December 26, 2017
    Assignee: viDA Therapeutics Inc.
    Inventor: Dale R. Cameron
  • Patent number: 9849113
    Abstract: Described herein are compounds for and methods of treating conditions or diseases in a subject by administering to the subject a pharmaceutical composition containing an effective amount of an ?-adrenergic modulator. The compounds and methods are also useful for alleviating types of pain, acute, neuropathic and chronic.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: December 26, 2017
    Assignee: Allergan, Inc.
    Inventors: Daniel W. Gil, John E. Donello, Wenkui K. Fang, Phong X. Nguyen, Ken Chow, Todd M. Heidelbaugh, Dario G. Gomez, Michael E. Garst, Santosh C. Sinha
  • Patent number: 9849114
    Abstract: Methods for treating fecal incontinence by administering to a subject in need thereof compositions including oxymetazoline as an active ingredient. Kits including compositions of oxymetazoline suitable for topical application, for the treatment of fecal incontinence.
    Type: Grant
    Filed: May 31, 2016
    Date of Patent: December 26, 2017
    Assignee: RDD Pharma Ltd.
    Inventors: Nir Barak, Howard Lawrence Rice
  • Patent number: 9849115
    Abstract: Provided herein are pharmaceutical formulations of dry-powder bendamustine suitable for pharmaceutical use. Also provided are methods of producing dry-powder bendamustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases.
    Type: Grant
    Filed: August 22, 2014
    Date of Patent: December 26, 2017
    Inventor: Vasilios Voudouris
  • Patent number: 9849116
    Abstract: Pharmaceutical compositions of (R)-pramipexole and one or more secondary therapeutic agents such as, for example, dopamine agonists, dopaminergic agonists, COMT inhibitors, MOA inhibitors, excitatory amino acid antagonists, growth factors, neurotrophic factors, antioxidants, anti-inflammatory agents, immunomodulators, anti-glutamatergics, ion channel blockers, ?-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonists, heat shock protein inducers/protein disaggregators and downregulators, monoamine oxidase type B (MOAB) inhibitors, multi-target agents, kinase inhibitors, Bcl inducers, histone deacetylase (HDAC) mediators, glial modulators, mitochondrial energy promoting agents, myostatin inhibitors, caspase inhibitors and combinations thereof or those related to mitochondrial dysfunction or increased oxidative stress are disclosed.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: December 26, 2017
    Assignee: Knopp Biosciences LLC
    Inventors: Michael E. Bozik, Valentin Gribkoff, Thomas Petzinger, Jr.
  • Patent number: 9849117
    Abstract: The present invention relates to 1-aza-bicycloalkyl derivatives of formula I, wherein X is CH2 or a single bond; Y is a group of formula and wherein R has the meanings as defined in the specification, which compounds are alpha 7 nicotinic acetylcholine receptor (nAChR) agonists; to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.
    Type: Grant
    Filed: January 4, 2017
    Date of Patent: December 26, 2017
    Assignee: Novartis AG
    Inventors: Dominik Feuerbach, Konstanze Hurth, Timothy John Ritchie, Rochdi Bouhelal
  • Patent number: 9849118
    Abstract: Disclosed in the present invention is a protein tyrosine phosphatase inhibitor. The preparation method therefor is: extracting the crude product from the Isaria Fumosorosea Wize solid or liquid fermentation broth using ethyl acetate, ethanol, methanol, or a mixed solvent of chloroform and methanol; separating the obtained extract using column chromatography on silica gel; and obtaining the target product. The inhibitor can be used to prepare pharmaceutical compositions for treating and preventing diabetes, obesity and cancers.
    Type: Grant
    Filed: May 7, 2013
    Date of Patent: December 26, 2017
    Assignee: Heibei University
    Inventors: Duqiang Luo, Jun Zhang, Zhiqin Liu
  • Patent number: 9849119
    Abstract: This application describes compounds that can act as opioid receptor ligands, which compounds can be used in the treatment of, for example, pain and pain related disorders.
    Type: Grant
    Filed: March 29, 2017
    Date of Patent: December 26, 2017
    Assignee: TREVENA, INC.
    Inventors: Dennis Yamashita, Dimitar Gotchev, Philip Pitis, Xiao-Tao Chen, Guodong Liu, Catherine C. K. Yuan
  • Patent number: 9849120
    Abstract: The present disclosure describes thiazole and pyridine carboxamide derivatives, their compositions and methods of use. The compounds inhibit the activity of the Pim kinases and are useful in the treatment of diseases related to the activity of Pim kinases including, e.g., cancer and other diseases.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: December 26, 2017
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Chu-Biao Xue, Yun-Long Li, Hao Feng, Ke Zhang
  • Patent number: 9849121
    Abstract: An aqueous liquid preparation containing (+)-(S)-4-[4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino]butyric acid or a pharmacologically acceptable acid addition salt thereof, which is stabilized with a water-soluble metal chloride, is provided.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: December 26, 2017
    Assignee: SENJU PHARMACEUTICAL CO., LTD.
    Inventor: Masayo Higashiyama
  • Patent number: 9849122
    Abstract: Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: December 26, 2017
    Assignee: Aerie Pharmaceuticals, Inc.
    Inventors: Casey Kopczynski, Cheng-Wen Lin, Jill Marie Sturdivant, Mitchell A. deLong
  • Patent number: 9849123
    Abstract: Compositions and methods for treatment of conditions affecting skin and/or mucosal surfaces of a subject that make use of an imidazoquinoline compound and a retinoid agent are described.
    Type: Grant
    Filed: August 17, 2017
    Date of Patent: December 26, 2017
    Assignee: 442 Ventures, LLC
    Inventor: J. Mark Jackson
  • Patent number: 9849124
    Abstract: Disclosed in certain embodiments is a method of treating or preventing an opioid induced adverse pharmacodynamic response comprising administering to a patient in need thereof an effective amount of buprenorphine.
    Type: Grant
    Filed: October 16, 2015
    Date of Patent: December 26, 2017
    Assignee: Purdue Pharma L.P.
    Inventors: Michele Hummel, Donald J. Kyle, Garth Whiteside
  • Patent number: 9849125
    Abstract: Described herein are abuse deterrent oral pharmaceutical compositions, methods for making the same, and methods of treatment using such compositions. In particular, oral pharmaceutical compositions that mitigate the risk of overingestion of one or more active pharmaceutical ingredients are described.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: December 26, 2017
    Assignee: Banner Lifie Sciences LLC
    Inventors: Chue Hue Yang, Tatyana Dyakonov, Nashwa El-Gendy, Jason M Vaughn, Justin R Hughey
  • Patent number: 9849126
    Abstract: The present disclosure describes a sterile formulation and method for treating an ear infection, especially otomycosis and otitis externa, by administering a one-time only treatment comprising an antibiotic, and antifungal, and an optional anti-inflammatory in a thick, otic carrier. In one embodiment, the sterilization comprises e-beam irradiating ingredients the formulation while heat-sterilizing other ingredients before combining under sterile condition.
    Type: Grant
    Filed: April 25, 2015
    Date of Patent: December 26, 2017
    Assignee: Entrx LLC
    Inventors: Matthew Branch, Vance Oglesbee
  • Patent number: 9849127
    Abstract: The present invention relates to a pharmaceutical composition comprising a compound of formula (I) and methods of treating or preventing cell proliferation disorders comprising administering to a subject a therapeutically active amount or a preventive amount of such a compound.
    Type: Grant
    Filed: May 14, 2014
    Date of Patent: December 26, 2017
    Assignee: Medizinisch Hochschule Hannover
    Inventors: Michael Heuser, Anuhar Chaturvedi, Matthias Preller
  • Patent number: 9849128
    Abstract: Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: December 26, 2017
    Assignees: Unity Biotechnology, Inc., Buck Institute for Research on Aging, Mayo Foundation for Medical Education and Research, The John Hopkins University
    Inventors: Remi-Martin Laberge, Judith Campisi, Albert Davalos, Marco Demaria, Nathaniel David, Alain Philippe Vasserot, James L. Kirkland, Tamar Tchkonia, Yi Zhu, Jennifer Elisseeff, Chaekyu Kim, Okhee Jeon
  • Patent number: 9849129
    Abstract: Provided are methods of treating a variety of disorders of the skin with inhibitors of the epithelial sodium channel (ENaC). The inhibitors are represented by formula (I)-(IV): where R is defined herein.
    Type: Grant
    Filed: February 18, 2016
    Date of Patent: December 26, 2017
    Assignee: PARION SCIENCES, INC.
    Inventors: Michael Ross Johnson, William Robert Thelin, Richard C. Boucher
  • Patent number: 9849130
    Abstract: Methods for treating a subject infected with Clostridium difficile comprises administering to the subject a synergistic combination of clofazimine and metronidazole. Pharmaceutical compositions comprising clofazimine and metronidazole are provided for treating Clostridium difficile infection and diseases or symptoms associated therewith.
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: December 26, 2017
    Assignee: KamTek, Inc.
    Inventors: Venkata M. Reddy, Wolf Prensky, Sharanjit VedBrat
  • Patent number: 9849131
    Abstract: The invention provides a compound of formula (Ia), and pharmaceutically acceptable salts thereof. The invention also provides use of the compounds or salts as modulators of Kv3.1 and/or Kv3.2, and in the treatment of diseases or disorders where a modulator of Kv3.1 and/or Kv3.2 is required, such as depression and mood disorders, hearing disorders, schizopherenea, substance abuse disorders, sleep disorders or epilepsy.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: December 26, 2017
    Assignee: AUTIFONY THERAPEUTICS LIMITED
    Inventors: Giuseppe Alvaro, Anne Decor, Stefano Fontana, Dieter Hamprecht, Charles Large, Agostino Marasco
  • Patent number: 9849132
    Abstract: The present invention relates to a product comprising a PDE1 inhibitor and a PDE2 inhibitor, in free or salt form, pharmaceutical compositions comprising them and their use as pharmaceuticals for the treatment of cAMP and/or cGMP related disorders.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: December 26, 2017
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Joseph Hendrick, Jennifer O'Brien, Gretchen Snyder, Peng Li, Lawrence P. Wennogle
  • Patent number: 9849133
    Abstract: The present invention relates to pharmaceutical formulations comprising xanthine or xanthine derivatives, kits thereof, and methods for treating fibrotic diseases by local administration.
    Type: Grant
    Filed: June 18, 2014
    Date of Patent: December 26, 2017
    Assignee: Eton Pharmaceuticals, Inc.
    Inventor: Matthew J. Buderer
  • Patent number: 9849134
    Abstract: A ?1-ADR agonist prodrug compound, which is hydrolysable in vivo to release a ?1-ADR agonist compound, and which prodrug compound contains a group which imparts greater lipophilicity and CNS bioavailability to the prodrug compound relative to the ?1-ADR agonist compound.
    Type: Grant
    Filed: February 18, 2015
    Date of Patent: December 26, 2017
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Mehrdad Shamloo, Bitna Yi, Pooneh Memar Ardestani
  • Patent number: 9849135
    Abstract: Disclosed herein are methods of treating or preventing a viral infection resulting from infection by a flavivirus, comprising administering to a subject a small molecule inhibitor of USP14, represented by Formula (I) or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, chemically-protected form, enantiomer or stereoisomer thereof, and pharmaceutical compositions comprising an effective amount of a compound of Formula (I) for use in the method.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: December 26, 2017
    Assignees: President and Fellows of Harvard College, Health Research, Inc.
    Inventors: Daniel J. Finley, Dilip Nag, Laura D. Kramer
  • Patent number: 9849136
    Abstract: A method for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor with compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is an optionally substituted thiazole, oxazole, isothiazole or isoxazole and X, R2, R3, R4, R5, R6, Ra and Rb are as defined herein.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: December 26, 2017
    Assignee: Roche Palo Alto LLC
    Inventors: Li Chen, Michael Patrick Dillon, Lichun Feng, Ronald Charles Hawley, Minmin Yang
  • Patent number: 9849137
    Abstract: A method of treating animals includes administering water soluble granules to an animal, where the water soluble granules include meloxicam, salt forming agent operable to form a meloxicam salt, a binder, and a carrier.
    Type: Grant
    Filed: July 28, 2014
    Date of Patent: December 26, 2017
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Stefan Henke, Martin A. Folger, Jens Lehmann, Diana C. Keilhofer, Hans-Juergen Kroff, Nina Herz
  • Patent number: 9849138
    Abstract: The present invention provides novel chemical compounds characterized as Rho kinase (ROCK) inhibitors, methods for their discovery, and their therapeutic, research, and diagnostic use. In particular, the present invention provides 1,4-benzodiazepine-2,5-dione compounds and related compounds having ROCK inhibitory activity, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with ROCK activity.
    Type: Grant
    Filed: September 4, 2015
    Date of Patent: December 26, 2017
    Assignee: The Regents of the University of Michigan
    Inventor: Gary D. Glick
  • Patent number: 9849139
    Abstract: Chemical entities that are kinase inhibitors, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: December 26, 2017
    Assignee: NeuPharma, Inc.
    Inventors: Xiangping Qian, Yong-Liang Zhu
  • Patent number: 9849140
    Abstract: Methods and compositions for stimulating the growth of hair are disclosed wherein said compositions include a cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compound represented by the formula I wherein the dashed bonds represent the presence or absence of a double bond which can be in the cis or trans configuration and A, B, Z, X, R1 and R2 are as defined in the specification and a penetration enhancer. Such compositions are used in stimulating hair growth of human or non-human animals.
    Type: Grant
    Filed: August 19, 2015
    Date of Patent: December 26, 2017
    Assignee: ALLERGAN, INC.
    Inventors: Kevin S. Warner, Kristin B. Prinn, Chetan P. Pujara, Pramod Sarpotdar, John T. Trogden, Adnan K. Salameh, Guang Wei Lu
  • Patent number: 9849141
    Abstract: The present invention relates to the use of spironolactone for the preparation of a pharmaceutical composition intended for preventing and/or treating multiple sclerosis. Alternatively, the invention relates to the use of spironolactone directly in T-lymphocytes or dendritic cells obtained from a blood sample taken from a patient and then injected back into the circulation. Therefore, the present invention relates to the use of a composition comprising spironolactone that can be used in the treatment of multiple sclerosis, which covers the administration of spironolactone directly or lymphocytes pre-treated with spironolactone, or dendritic cells to individuals requiring such treatment. Spironolactone is an orally administered drug that is less expensive than many of the treatments available for MS and, furthermore, has the advantage of being a known compound already used in humans for extended periods and therefore the adverse effects thereof have been described in clinical studies.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: December 26, 2017
    Assignee: PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE
    Inventors: Alexis M. Kalergis, Andres A. Herrada
  • Patent number: 9849142
    Abstract: Methods of treatment and dosage regimes using hydrophobic gel or foam compositions comprising a tetracycline antibiotic for accelerating the return of skin integrity and or in treating or alleviating a disorder including impetigo, acne, rosacea, a skin disease caused by a bacteria or a tetracycline antibiotic responsive disease, wherein the foam composition or gel is administered topically to a target area on a subject having the disorder and wherein the target area comprises an area of skin, or mucosa or an eye.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: December 26, 2017
    Assignee: Foamix Pharmaceuticals Ltd.
    Inventors: Dov Tamarkin, Elana Gazal, Rita Keynan, Meir Eini, David Schuz
  • Patent number: 9849143
    Abstract: A method for the prevention or treatment of Influenza virus infection or Adenovirus infection by administering an effective amount of a compound of Formula (I), Formula (II), or similar compound to an individual in need is provided.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: December 26, 2017
    Assignee: The Burlington HC Research Group, Inc.
    Inventors: Dale M. Walker, Adriana Elisa Kajon, Vernon E. Walker
  • Patent number: 9849144
    Abstract: Pharmaceutical compositions comprising glutamine and trehalose for treating side effects to oncology treatments are disclosed.
    Type: Grant
    Filed: August 27, 2014
    Date of Patent: December 26, 2017
    Assignee: Healios Oncology Nutrition, LLC
    Inventor: Peter Meade Anderson